ATE533785T1 - Peptidfragmente zur induzierung der synthese extrazellulärer matrixproteine - Google Patents

Peptidfragmente zur induzierung der synthese extrazellulärer matrixproteine

Info

Publication number
ATE533785T1
ATE533785T1 AT07796001T AT07796001T ATE533785T1 AT E533785 T1 ATE533785 T1 AT E533785T1 AT 07796001 T AT07796001 T AT 07796001T AT 07796001 T AT07796001 T AT 07796001T AT E533785 T1 ATE533785 T1 AT E533785T1
Authority
AT
Austria
Prior art keywords
seq
inducing
synthesis
extracellular matrix
peptide fragments
Prior art date
Application number
AT07796001T
Other languages
German (de)
English (en)
Inventor
Scott Harris
Timothy Falla
Lijuan Zhang
Original Assignee
Helix Biomedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helix Biomedix Inc filed Critical Helix Biomedix Inc
Application granted granted Critical
Publication of ATE533785T1 publication Critical patent/ATE533785T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Birds (AREA)
  • Zoology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
AT07796001T 2006-06-13 2007-06-12 Peptidfragmente zur induzierung der synthese extrazellulärer matrixproteine ATE533785T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81328406P 2006-06-13 2006-06-13
PCT/US2007/013748 WO2007146269A2 (en) 2006-06-13 2007-06-12 Peptide fragments for inducing synthesis of extracellular matrix proteins

Publications (1)

Publication Number Publication Date
ATE533785T1 true ATE533785T1 (de) 2011-12-15

Family

ID=38664422

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07796001T ATE533785T1 (de) 2006-06-13 2007-06-12 Peptidfragmente zur induzierung der synthese extrazellulärer matrixproteine

Country Status (19)

Country Link
US (5) US8110658B2 (enExample)
EP (5) EP3002294B8 (enExample)
JP (2) JP5535620B2 (enExample)
CN (2) CN101472944B (enExample)
AT (1) ATE533785T1 (enExample)
AU (1) AU2007258387B2 (enExample)
BR (2) BR122018002612B8 (enExample)
CA (4) CA2947349A1 (enExample)
CY (1) CY1112241T1 (enExample)
DK (3) DK2409988T3 (enExample)
ES (4) ES2680022T3 (enExample)
HK (1) HK1210791A1 (enExample)
HU (2) HUE027273T2 (enExample)
MX (2) MX2008016011A (enExample)
PL (4) PL2402369T3 (enExample)
PT (2) PT2402369E (enExample)
RU (2) RU2501807C2 (enExample)
SI (2) SI2027152T1 (enExample)
WO (1) WO2007146269A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3002294B8 (en) * 2006-06-13 2018-05-16 Helix Biomedix Inc. Peptide fragments for inducing synthesis of extracellular matrix proteins
ES2421262T3 (es) * 2007-11-30 2013-08-30 Evonik Goldschmidt Gmbh Composición para el cuidado personal y cosmética que contiene tetrapéptidos con las unidades CX1X2G, PX1X2P o PX1X2K
WO2009111471A2 (en) * 2008-03-03 2009-09-11 Henry Ford Health System Collagen-derived peptide as biomarker, therapeutic agent and target
EP2235038B1 (de) * 2008-12-30 2019-06-05 GKL-Biotec AG Tetrapeptidkombination
US8716438B2 (en) * 2009-10-09 2014-05-06 University of Pittsburgh—of the Commonwealth System of Higher Education Matricryptic ECM peptides for tissue reconstruction
WO2014004719A2 (en) 2012-06-26 2014-01-03 Worcester Polytechnic Institute Matrix scaffold with antimicrobial activity
ES2633437T3 (es) * 2013-02-14 2017-09-21 Helix Biomedix, Inc. Péptidos bioactivos cortos para promover la cicatrización de heridas
CN105189531B (zh) 2013-03-13 2020-02-21 安特易斯有限公司 用于皮肤复新的肽及其使用方法
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
ES2631804T3 (es) * 2013-06-14 2017-09-05 Helix Biomedix Inc. Tetrapéptidos derivados de quimiocinas humanas C-X-C útiles para el tratamiento de diversas afecciones de la piel
US10385115B2 (en) 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
KR20180033586A (ko) 2015-08-04 2018-04-03 듀크 유니버시티 전달을 위한 유전적으로 인코딩된 내재적으로 무질서화된 스텔스 중합체 및 이의 이용 방법
KR101916522B1 (ko) 2015-09-25 2018-11-08 경상대학교산학협력단 굴 가수분해물의 제조방법 및 이로부터 분리된 펩타이드
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
US11135301B2 (en) 2016-09-14 2021-10-05 Duke University Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
EP3515928A4 (en) 2016-09-23 2020-04-01 Duke University Unstructured non-repetitive polypeptides having lcst behavior
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
JP6489486B2 (ja) * 2017-01-20 2019-03-27 富比積生物科技股▲分▼有限公司 ペンタペプチド／ヘキサペプチドにより変形性関節症を治療するための新規用途
JP6489487B2 (ja) * 2017-01-20 2019-03-27 富比積生物科技股▲分▼有限公司 テトラペプチド−３ ｇｅｋｇまたはペンタペプチド−３ ｇｅｋｇｆにより変形性関節症を治療するための新規用途
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
US11680083B2 (en) 2017-06-30 2023-06-20 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
US12296018B2 (en) 2018-01-26 2025-05-13 Duke University Albumin binding peptide-drug (AlBiPeD) conjugates and methods of making and using same
US12257308B2 (en) 2018-04-30 2025-03-25 Duke University Stimuli-responsive PEG-like polymer-based drug delivery platform
WO2020028806A1 (en) 2018-08-02 2020-02-06 Duke University Dual agonist fusion proteins
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
EP4000595A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
EP4000598A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
EP4000596A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
EP4000597A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
EP4140473A1 (en) * 2021-08-27 2023-03-01 The Boots Company plc Cosmetic compositions
CN115990240A (zh) * 2021-10-20 2023-04-21 富比积生物科技股份有限公司 寡肽在治疗牙龈发炎、牙龈萎缩及修复口腔黏膜中的用途
CN114437238B (zh) * 2022-01-26 2024-03-26 浙江工业大学 胶原蛋白肽-牛乳铁蛋白肽融合蛋白、基因及其表达方法
CN115894615A (zh) * 2022-10-19 2023-04-04 上海高科生物工程有限公司 一种抗皮肤衰老的五肽衍生肽段ys及其应用
CN116375847B (zh) * 2022-10-26 2025-06-13 江苏创健医疗科技股份有限公司 酵母重组xvii型人源化胶原蛋白及其制备方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU466760B2 (en) * 1972-03-14 1975-11-06 Takeda Chemical Industries Ltd. Process for producing peptide
US5064430A (en) * 1985-10-31 1991-11-12 Uab Research Foundation Polynonapeptide bioelastomers having an increased elastic modulus
JP2573006B2 (ja) * 1987-12-17 1997-01-16 富士薬品工業株式会社 新規なヒドロキサム酸誘導体
WO1989010099A1 (en) * 1988-04-21 1989-11-02 Uab Research Foundation Bioelastomeric materials suitable for the protection of wound repair sites from the occurrence of adhesions
DE69033436T2 (de) 1989-04-10 2000-06-21 Helix Biomedix, Inc. Lytische peptide, verwendung als wachstumsfördernde mittel und für infektionen und krebs
US5679770A (en) * 1991-11-08 1997-10-21 Mochida Pharmaceutical Co., Ltd. Polypeptide, DNA fragment encoding the same, drug composition containing the same and process for producing the same
JP3100005B2 (ja) * 1992-07-28 2000-10-16 雪印乳業株式会社 ヒト免疫不全ウィルス感染・増殖抑制剤
US6132976A (en) * 1992-12-04 2000-10-17 Shriners Hospitals For Children Immunoassays for the measurement of collagen denaturation and cleavage in cartilage
IL104954A (en) * 1993-03-04 2006-08-01 Yissum Res Dev Co Use of osteogenic oligopeptides in the preparation of pharmaceutical compositions for the treatment of bone diseases and some such novel oligopeptides, pharmaceutical compositions containing them and their preparation
US5561107A (en) 1993-06-04 1996-10-01 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
JPH07227281A (ja) * 1994-02-15 1995-08-29 Agency Of Ind Science & Technol ペプチダーゼ及びその製造法
US5763576A (en) * 1995-10-06 1998-06-09 Georgia Tech Research Corp. Tetrapeptide α-ketoamides
US6159940A (en) * 1996-02-28 2000-12-12 Immunotech Developments Inc. Method for modulating hemopoiesis
DE19651099A1 (de) * 1996-12-09 1998-06-10 Consortium Elektrochem Ind Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung
EP1074620A1 (en) * 1999-08-06 2001-02-07 HyGene AG Monomeric protein of the TGF-beta family
EP0858808B1 (en) * 1997-01-17 2003-04-02 Johnson & Johnson Medical Ltd. Peptides for use in wound treatment
US6639050B1 (en) * 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
GB2341182A (en) * 1998-09-01 2000-03-08 Yamanouchi Uk Ltd Protein comprising amino acid sequences having SH3 domain binding activity and nuclear localisation activity
US6747135B1 (en) * 1998-10-16 2004-06-08 The Board Of Trustees For The Leland Stanford Junior University Fluorescent dye binding peptides
US6492326B1 (en) * 1999-04-19 2002-12-10 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
CA2276542C (en) * 1999-06-28 2013-07-30 Vladislav I. Deigin Novel peptide, a method for its preparation and a pharmaceutical composition containing the peptide
CN1280983A (zh) * 1999-07-16 2001-01-24 王革 白细胞介素－11的衍生物及其制备方法
US6627785B1 (en) * 2000-02-29 2003-09-30 Virginia Commwealth University Wound dressings with protease-lowering activity
AU2001255448A1 (en) * 2000-04-17 2001-10-30 Stephen B. Liggett Alpha-2 adrenergic receptor polymorphisms
US20030166510A1 (en) * 2000-10-11 2003-09-04 Pickart Loren R. Methods and compositions for increasing skin remodeling
GB0029777D0 (en) * 2000-12-06 2001-01-17 Regen Therapeutics Plc Peptides
ES2389285T3 (es) 2001-03-28 2012-10-24 Helix Biomedix, Inc. Péptidos bioactivos cortos y procedimientos para su uso
US7186693B2 (en) * 2001-08-16 2007-03-06 Kimberly - Clark Worldwide, Inc. Metalloproteinase inhibitors for wound healing
US7041506B2 (en) * 2001-11-19 2006-05-09 Becton Dickinson And Company Peptides promoting cell adherence, growth and secretion
CA2468187A1 (en) * 2001-11-28 2003-06-05 Becton, Dickinson And Company Peptides with growth inhibitory action
US20040009911A1 (en) * 2002-01-31 2004-01-15 Irm, Llc Hepsin substrates and prodrugs
EP1504033A2 (en) * 2002-05-03 2005-02-09 Millenium Biologix Inc. Connective tissue stimulating peptides
EP1576352B1 (en) * 2002-09-09 2010-04-14 University Of Cincinnati Methods of cardiovascular disease assessment in an individual
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
TWI256893B (en) * 2003-03-25 2006-06-21 Fancl Corp Composition for promoting production of type I collagen and/or elastin
DE10339180A1 (de) * 2003-08-21 2005-03-24 Deutsche Gelatine-Fabriken Stoess Ag Kollagenhydrolysat
US7638318B2 (en) 2003-09-26 2009-12-29 Norvartis Ag Seneca Valley virus based compositions and methods for treating disease
JP4256389B2 (ja) 2003-11-17 2009-04-22 セダーマ テトラペプチドとトリペプチドの混合物を含む組成物
JP2005245285A (ja) * 2004-03-03 2005-09-15 National Institute Of Advanced Industrial & Technology コラーゲン分解物の製造方法
DE102005000868A1 (de) * 2004-10-15 2006-04-20 Henkel Kgaa Zusammensetzungen mit Inhibitoren der Prostaglandin- und/oder Leukotrien-Synthese in Kombination mit Stimulatoren der Freisetzung kutaner Neuromediatoren
DE202004012807U1 (de) * 2004-08-13 2004-10-21 Henkel Kgaa Kosmetische und dermatologische Zusammensetzungen mit DNA-Reparaturenzymen und Oligopeptiden
DE102004050563A1 (de) * 2004-10-15 2006-04-20 Henkel Kgaa Kosmetische und der dermatologische Zusammensetzungen mit Wirkstoffen für einen verbesserten Hautkomfort
DE102004055541A1 (de) * 2004-11-17 2006-05-18 Henkel Kgaa Kosmetische und dermatologische Zusammensetzungen zur Behandlung reifer Haut
US20060046271A1 (en) * 2004-09-02 2006-03-02 Vanderbilt University Assessment of cancer susceptibility to molecular targeted therapy by use of recombinant peptides
GB2434367B (en) * 2004-10-05 2010-05-12 Diversa Corp Improved vaccines
WO2006042661A2 (en) * 2004-10-18 2006-04-27 Cognis France S.A.S Oligopeptides and their use in cosmetics
WO2006048339A2 (en) * 2004-11-04 2006-05-11 L'oréal Cosmetic composition comrising an active agent and a urea compound
US20070224150A1 (en) * 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
FR2884418B1 (fr) * 2005-04-15 2008-11-21 Soc Extraction Principes Actif Utilisation d'un peptide comme principe actif amincissant
WO2007004869A2 (en) * 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
DE102005063062A1 (de) * 2005-12-29 2007-07-05 Henkel Kgaa Synergistische Proteinhydrolysat-Kombinationen zur Behandlung reifer Haut
US7807625B2 (en) * 2006-01-18 2010-10-05 Grant Industries, Inc Anti-wrinkle composition
EP3002294B8 (en) * 2006-06-13 2018-05-16 Helix Biomedix Inc. Peptide fragments for inducing synthesis of extracellular matrix proteins

Also Published As

Publication number Publication date
PT2402369E (pt) 2016-02-19
AU2007258387B2 (en) 2012-08-16
US9447143B2 (en) 2016-09-20
JP5844834B2 (ja) 2016-01-20
EP2940042A2 (en) 2015-11-04
HK1210791A1 (en) 2016-05-06
ES2545219T3 (es) 2015-09-09
US8658764B2 (en) 2014-02-25
US8962798B2 (en) 2015-02-24
CY1112241T1 (el) 2015-12-09
RU2011141572A (ru) 2013-04-20
US20150094270A1 (en) 2015-04-02
US8110658B2 (en) 2012-02-07
US20170157196A1 (en) 2017-06-08
CA2655116A1 (en) 2007-12-21
CA2947349A1 (en) 2007-12-21
AU2007258387A1 (en) 2007-12-21
SI2409988T1 (sl) 2015-10-30
EP2409988A3 (en) 2012-05-09
EP2409988A2 (en) 2012-01-25
EP2027152A2 (en) 2009-02-25
HUE026698T2 (en) 2016-07-28
PL2409988T3 (pl) 2015-12-31
DK2402369T3 (en) 2016-02-01
MX361694B (es) 2018-12-10
CN101472944A (zh) 2009-07-01
CA2835369A1 (en) 2007-12-21
HK1161599A1 (en) 2012-07-27
CN101472944B (zh) 2014-05-28
WO2007146269A3 (en) 2008-08-14
RU2441877C2 (ru) 2012-02-10
JP5535620B2 (ja) 2014-07-02
EP2409988B1 (en) 2015-07-22
ES2375413T3 (es) 2012-02-29
BR122018002612B8 (pt) 2021-07-27
EP2402369B1 (en) 2015-11-25
HK1217346A1 (en) 2017-01-06
EP3002294B1 (en) 2018-03-28
ES2680022T3 (es) 2018-09-03
EP3002294A3 (en) 2016-06-22
AU2007258387A2 (en) 2009-02-19
US20070299015A1 (en) 2007-12-27
CA2655116C (en) 2016-12-13
JP2009539987A (ja) 2009-11-19
ES2557402T3 (es) 2016-01-25
BRPI0713153B8 (pt) 2021-05-25
US20120093740A1 (en) 2012-04-19
BRPI0713153B1 (pt) 2019-05-14
SI2027152T1 (sl) 2012-03-30
WO2007146269A2 (en) 2007-12-21
CA2947353A1 (en) 2007-12-21
US20140066380A1 (en) 2014-03-06
PT2409988E (pt) 2015-10-12
US10376557B2 (en) 2019-08-13
MX2008016011A (es) 2009-02-13
PL2402369T3 (pl) 2016-05-31
EP3002294B8 (en) 2018-05-16
RU2009100884A (ru) 2010-07-20
DK2409988T3 (en) 2015-09-14
DK2027152T3 (da) 2012-02-20
RU2501807C2 (ru) 2013-12-20
BR122018002612B1 (pt) 2021-01-19
PL3002294T3 (pl) 2018-08-31
EP3002294A2 (en) 2016-04-06
EP2402369A3 (en) 2012-05-16
PL2027152T3 (pl) 2012-04-30
EP2402369A2 (en) 2012-01-04
HUE027273T2 (en) 2016-10-28
BRPI0713153A2 (pt) 2012-03-27
EP2940042A3 (en) 2016-02-17
CA2835369C (en) 2017-01-31
CN104017071A (zh) 2014-09-03
JP2014129369A (ja) 2014-07-10
CN104017071B (zh) 2017-08-15
HK1161600A1 (en) 2012-07-27
HK1128700A1 (en) 2009-11-06
EP2027152B1 (en) 2011-11-16

Similar Documents

Publication Publication Date Title
ATE533785T1 (de) Peptidfragmente zur induzierung der synthese extrazellulärer matrixproteine
BR112012017345A2 (pt) "composições e métodos de pgl para a produção aumentada de isopreno e outros produtos com 6-fosfogliconolactonase (pgl)"
EP2520590A3 (en) Cross-species-specific binding domain
UA117216C2 (uk) Пухлиноасоційований пептид та його застосування
MX2009012650A (es) Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
JP2009539987A5 (enExample)
NZ597580A (en) Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof
PT1928882E (pt) (s)-n-metilnaltrexona, processo para a sua síntese e sua utilização farmacêutica
AR070058A1 (es) Enzima bacteriana asociada con la sintesis de ecuol
DE602004001727D1 (de) Verfahren zur herstellung cyclischer peptide
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
ATE506957T1 (de) Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen
ATE500265T1 (de) Synthetische mecp2-sequenz für die proteinersatztherapie
BRPI0406037A (pt) Produto de carne ou análogo de carne contendo soja, e, método para preparar o mesmo
CL2007003223A1 (es) Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.
ATE449790T1 (de) Rekombinante gelatinepartikel für die zelladhäsion
NZ589743A (en) Anxiolytic composition containing alphas1-casein-derived peptides
WO2009105780A3 (en) Mntf peptide compositions and methods of use
ATE544779T1 (de) Neue, die migration dendritischer zellen induzierende polypeptide, sowie medikamente und pharmazeutische zusammensetzungen, die diese enthalten
MX2010005597A (es) Péptidos inmunoreguladores novedosos, composiciones y usos de los mismos.
CY1117084T1 (el) Θραυσματα πεπτιδιου για την επαγωγη συνθεσης πρωτεϊνων εξωκυτταριας μητρας
Ma et al. Progress in Research on Animal Collagen Peptides: Preparation, Bioactivity, and Application
CU23558A1 (es) Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
UA36367U (ru) Способ культивирования каллусной ткани первоцвету весеннего (primula veris)
ATE370154T1 (de) Verfahren zur direkten synthese von oligorhamnosiden, oligorhamnosidhaltige zusammensetzung und verwendung davon als medikament